Trading Concept
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Trading Concept
No Result
View All Result
Home Trading News

Moderna says booster of its Covid vaccine appears to protect against omicron

by
December 20, 2021
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Stocks are trying to break out of their summer range, but key tests lie ahead

Boeing Dreamliner deliveries to resume in the ‘coming days,’ FAA says

In this article

MRNA

Empty bottles of Moderna Covid-19 vaccine are pictured in a vaccination center in Garlan, western France, on December 13, 2021.
FRED TANNEAU | AFP | Getty Images

Moderna announced Monday that a third dose of its mRNA vaccine against Covid-19 appears to provide significant protection against the omicron variant.

Moderna said that its currently authorized booster can “boost neutralizing antibody levels 37-fold higher than pre-boost levels,” which it described as reassuring.

However, it also said that a double doze of the booster shot — 100 micrograms, rather than the approved 50 micrograms — was significantly more effective. A 100 microgram booster dose increased neutralizing antibody levels “approximately 83-fold,” according to preliminary data, it said in a release.

The 100 microgram dose of its booster shot was “generally safe and well tolerated,” Moderna said, though “there was a trend toward slightly more frequent adverse reactions following the 100 [microgram] booster dose relative to the authorized 50 [microgram] dose.”

Without a booster, the company’s vaccine, called mRNA-1273, was been found to be far less effective against the fast-spreading omicron variant, generating low neutralizing antibodies.

The company said it will also continue to develop an omicron-specific booster candidate which should enter clinical trials in early 2022.

The decision to focus on its current Covid-19 booster, rather than immediately developing a variant-specific vaccine, was because of both the speed of omicron’s spread and its confidence in its current offering, the company said.

“Moving forward, given the strength of the mRNA-1273 and the speed at which the Omicron variant is spreading, Moderna’s first line of defense against Omicron will be a booster dose of mRNA-1273,” the company said in its statement.

“Given the long-term threat demonstrated by Omicron’s immune escape, Moderna will also continue to develop an Omicron-specific variant vaccine (mRNA-1273.529) that it expects to advance into clinical trials in early 2022 and will evaluate including Omicron in its multivalent booster program.”

The data have not yet been peer reviewed.

The news comes as the World Health Organization warns omicron cases can double every 1.5 to 3 days in areas of local spread. The U.K. recorded its highest daily case levels since the start of the pandemic in the last week, and the Netherlands imposed a strict full lockdown on Sunday extending past the new year.

ShareTweetPin

Related Posts

Stocks are trying to break out of their summer range, but key tests lie ahead

by
August 8, 2022
0

Stocks are testing the top of this summer's range, an important level of resistance that could help determine the duration...

Boeing Dreamliner deliveries to resume in the ‘coming days,’ FAA says

by
August 8, 2022
0

In this article BA An American Airlines Boeing 787-9 Dreamliner approaches for a landing at the Miami International Airport on...

Malcolm Gladwell says it’s ‘not in your best interest to work from home.’ Nearly 20 years ago he said he ‘hates desks’ and writes from his couch

by
August 8, 2022
0

',panelEmptyTemplate=' {emptyPanelMsg} ',panelErrorTemplate=' {errorMsg} ',panelParentTemplate='',notifOnboardPromoTemplate='',EXPANDED_PANEL="expanded_panel",ERROR_PANEL="error_panel",NotificationView=function(){function e(n,t){classCallCheck(this,e);var i=this;i._config=n,i._panelNode=null,i._store=t}return createClass(e,[{key:"_generatePanelMarkup",value:function(e,n){var t=this._config,i=void 0,o=void 0;"undefined"!=typeof window&&(i=window.Notification&&"default"===window.Notification.permission,o=t.promos.bypassEligibleClassCheck||hasClass(document.body,t.promos.eligibleBodyClass));var r=t.promos.enableNotifOnboard&&i&&o?notifOnboardPromoTemplate:"";if(r){var s=t.promos.showYahooLogo?"":"yns-no-logo";r=r.replace("{notifOnboardBtnLabel}",t.promos.notifOnboardBtnLabel).replace("{notifOnboardMsg}",t.promos.notifOnboardMsg).replace("{subscriptionTopic}",t.promos.subscriptionTopic).replace("{noLogoClass}",s).replace("{promoLogo}",t.promos.promoLogo)}var a=n.newCount>t.panel.maxCount?n.newCount:"",c=t.panel.notificationCenterPath,l=c?"":constants.panelHideElement,d=t.panel.headerMsg?"":" "+constants.panelHideElement,u=c?constants.panelPaddingBtm:"",p=void 0;n.count?p=n.markup:p=panelEmptyTemplate.replace("{emptyPanelMsg}",t.panel.emptyPanelMsg);return e=e.replace("{notifMarkup}",p).replace("{promoMarkup}",r).replace("{hideClass}",l).replace("{notifCenterLink}",c).replace("{paddingClass}",u).replace("{headerMsg}",t.panel.headerMsg).replace("{hideHeaderClass}",d).replace(/{notificationCenterNavMsg}/g,t.panel.notificationCenterNavMsg).replace(/{newCount}/g,a)}},{key:"render",value:function(e,n){var t=this;if(t._panelNode){var i=void...

McDonald’s Menu Move Targets Wendy’s, Burger King

by
August 8, 2022
0

Fast food has always been a reactionary business. McDonald's (MCD) - Get McDonald's Corporation Report created the Big Mac in...

Axios to sell itself to Cox Enterprises for $525 million

by
August 8, 2022
0

Jim VandeHei, Co-Founder and CEO of Axios speaks at the 2022 Milken Institute Global Conference in Beverly Hills, California, May...

Next Post

Omicron casts a shadow over winter holidays as countries consider strict restrictions

Stocks making the biggest moves premarket: Moderna, Royal Caribbean, Cerner and others

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • WHO says Covid vaccine booster programs will prolong pandemic

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Spin or Split? AT&T Has a Big Decision to Make on Discovery Stake.

    0 shares
    Share 0 Tweet 0
  • Here’s how Carl Icahn is positioning for a possible recession in America

    0 shares
    Share 0 Tweet 0
  • Some lawmakers and their families are betting thousands of dollars on crypto

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by tradingconcept.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.tradingconcept.net